Clinical trials: Vehicle
Alcohol Drinking, Alcohol Intoxication
Evaluating Perceived Fitness to Drive While Intoxicated
The goal of this study is to conduct a laboratory-based pilot randomized control trial of smartphone-enabled breath alcohol monitoring on perceived fitness to drive a vehicle among intoxicated adults.
- Conditions
- Alcohol Drinking, Alcohol Intoxication, Perception, Self, Drinking, Alcohol
- Trial name
- NCT05028413
- Testing
- Participants Shown their Breath Alcohol Content Measurement
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Psoriasis
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s) (Cohort 1).
- Trial name
- NCT03392168
- Testing
- ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream
- Where
- 8 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Psoriasis
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
The objectives of this study are to compare the safety of DFD01 Spray to Comp01 Lotion for topical treatment of moderate plaque psoriasis and to compare the efficacy of DFD01 Spray to Placebo Spray for topical treatment of…
- Trial name
- NCT01947491
- Testing
- DFD01 Spray, Comp01 Lotion, Vehicle Lotion
- Where
- 40 sites in United States
- Volunteers
- 394 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Onychomycosis
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
This study will examine the safety, tolerability and efficacy of NVXT in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.
- Trial name
- NCT02343627
- Testing
- NVXT Solution, Vehicle of test product
- Volunteers
- 47 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Acne Vulgaris
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
- Trial name
- NCT02073461
- Testing
- CD1579 2.5%, CD1579 5%, Vehicle
- Where
- 6 sites in Japan
- Volunteers
- 236 people
- Sponsor
- Galderma R&D
Molluscum Contagiosum
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC.
- Trial name
- B-SIMPLE2 (NCT03927703)
- Testing
- SB206 12%
- Where
- 27 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novan, Inc.
Glaucoma
A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma
The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients with glaucoma.
- Trial name
- NCT01426113
- Testing
- bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
- Where
- 9 sites in United States, France and 5 more
- Volunteers
- 6 people
- Sponsor
- Allergan
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients
The scope of this multicenter, double blind, randomized, vehicle-controlled clinical investigation is to evaluate and confirm the performance and safety of the Relizema cream in the improvement of the dermatitis severity in…
- Trial name
- YOUNG (NCT05259774)
- Testing
- Relizema cram
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Relife S.r.l.
Malignant Glioma, Glioblastoma
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
- Trial name
- NCT01454596
- Testing
- Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Alcohol Drinking, Drinking Behavior
Behavior Brain Responses
To compare responses to acute oral doses of ethanol in healthy young adults who experience mainly stimulant subjective effects from the drug or mainly sedative effects.
- Conditions
- Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
- Trial name
- BBR (NCT03964350)
- Testing
- Ethanol
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Asthma
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests.
- Trial name
- NCT00296491
- Testing
- fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP)
- Where
- 121 sites in United States, Canada and 2 more
- Volunteers
- 725 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex
Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection
This study will evaluate the safety and blood levels of a new pediatric formulation of Famvir in children 1-12 years of age. In Part A, patients will receive a single dose of famciclovir (12.5 mg/kg) to assess pharmacokinetics…
- Trial name
- NCT00098059
- Testing
- Famciclovir
- Where
- 13 sites in United States, Panama
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Study of 0416 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0416 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01053247
- Testing
- 0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
- Where
- United States
- Volunteers
- 793 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Open-Angle Glaucoma, Ocular Hypertension
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with…
- Trial name
- NCT02419508
- Testing
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Alcon Research
Lung Cancer
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062439
- Testing
- cisplatin, docetaxel, etoposide
- Where
- 154 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.